Srra stock zacks

Stock News - TD Ameritrade

SRRA Sierra Oncology, Inc. Stock Quote - FINVIZ.com Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Zacks: Brokerages Set $74.00 Price Target for Sierra ... Shares of Sierra Oncology Inc (NASDAQ:SRRA) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating. Brokers have set a one year consensus target price of $74.00 for the company […] SRRA Sierra Oncology Inc — Stock Price and ... - StockTwits Apr 03, 2020 · Real-time trade and investing ideas on Sierra Oncology Inc SRRA from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal.

SRRA | Complete Sierra Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Feb. 26, 2020 at 8:47 a.m. ET on Zacks.com.

SRRA's NASDAQ Last Sale (NLS) "Last Sale" is the price at which a stock last traded during regular market hours. NLS Volume "Volume" is the number of shares of the stock traded on the listing exchange during regular trading hours. Previous Close Today's High / Low 52 Week High / Low SRRA - Sierra Oncology Stock Price - Barchart.com Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a … Zacks: Brokerages Expect Sierra Oncology Inc (NASDAQ:SRRA ... Wall Street analysts forecast that Sierra Oncology Inc (NASDAQ:SRRA) will post earnings of ($3.17) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Sierra Oncology’s earnings. The lowest EPS estimate is ($3.60) and the highest is ($2.73). Sierra Oncology posted earnings of ($7.60) per share during the […]

Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings. Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon. Simply Wall St. Do Institutions Own Shares In Sierra Oncology

Why Earnings Season Could Be Great for Sierra Oncology (SRRA) Feb 26, 2020 · This suggests that analysts have very recently bumped up their estimates for SRRA, giving the stock a Zacks Earnings ESP of +13.74% heading into earnings season. Sierra Oncology, Inc. Common Stock (SRRA) Earnings Report ... Find the latest Earnings Report Date for Sierra Oncology, Inc. Common Stock (SRRA) at Nasdaq.com. Looking for additional market data? According to Zacks Investment Research, based on 2 SRRA Stock Quote - Sierra Oncology, Inc. Common Stock ... Mar 30, 2020 · Stock quote for Sierra Oncology, Inc. Common Stock Common Stock (SRRA) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.

Sierra Oncology, Inc. (SRRA) latest stock news & headlines ...

Investors Overview; News Release; Events & Webcasts; Presentations; Financial Reporting; Quarterly Results; Stock Information; Corporate Governance; FAQs  3 Reasons Why Algonquin Power & Utilities (AQN) Is a Great Growth Stock The Zacks Analyst Blog Highlights: Western Digital, Cardinal Health, HP, Lennar and KB FPRX 3.4100 +3.33%CBAY 1.5400 -5.52%SRRA 11.6000 - 3.57%. Jul 24, 2017 Exchange Commission ("SEC") as a national stock exchange on June 17, 2016 and began business KraneShares Zacks New China ETF.

Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.

Jan 28, 2020 · Estimates have actually risen so much that the stock now has a Zacks Rank #1 (Strong Buy) suggesting this relatively unloved stock could be due for a breakout soon. This will be especially true if SRRA stock can build momentum from here and find a way to continue higher of off this encouraging trading development. SRRA Stock News - Fidelity Apr 03, 2020 · VANCOUVER, Feb. 6, 2020 Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that the Series A convertible voting preferred stock ProNAi Therapeutics - Stock Split History | SRRA | MacroTrends Stock split history for ProNAi Therapeutics since 2020. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values. Analysts Anticipate Sierra Oncology Inc (NASDAQ:SRRA) to ... Sierra Oncology Inc (NASDAQ:SRRA) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Zacks Investment Research cut shares of Sierra Oncology (NASDAQ:SRRA) from a hold rating to a sell rating in a report published on Saturday morning, Zacks.com reports.. According to Zacks, “Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. Sierra Oncology, Inc. (SRRA) stock price, quote, history ... Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings. Sierra Oncology has been struggling lately, but the selling pressure may be coming to an end soon. Simply Wall St. Do Institutions Own Shares In Sierra Oncology Sierra Oncology (NASDAQ:SRRA) Downgraded by Zacks ... Zacks Investment Research lowered shares of Sierra Oncology (NASDAQ:SRRA) from a hold rating to a sell rating in a research note released on Saturday morning, Zacks.com reports. According to Zacks Sierra Oncology (NASDAQ:SRRA) Downgraded to “Hold” at ...